ophthalmic protein peptide drug delivery
TRANSCRIPT
![Page 1: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/1.jpg)
OPHTHALMIC PROTEIN AND PEPTIDE DELIVERY
DEPARTMENT OF PHARMACEUTICS
AISSMS COLLEGE OF PHARMACY PUNE
24 SEPTEMBER 2009
04/08/23 1
![Page 2: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/2.jpg)
CONTENTS
• INTRODUCTION TO OPHTHALMIC PREPARATIONS
• ANATOMY & PHYSIOLOGY OF EYE• CORNEAL ABSORPTION & DRUG ACCESS• TYPES OF OPHTHALMIC DOSAGE FORMS• CHARACTERISTICS OF OPHTHALMIC
PREPARATIONS
04/08/23 2
![Page 3: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/3.jpg)
• INTRODUCTION TO PEPTIDES & PROTEINS• CLASSIFICATION OF PROTEINS • FUNCTIONS OF PROTEINS• STRUCTURE OF PROTEINS• BIOMEDICAL IMPORTANCE OF PROTEINS• NEED FOR PROTEIN & PEPTIDE DRUG DELIVERY
04/08/23 3
![Page 4: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/4.jpg)
• PEPTIDES AND EYE • MECHANISM OF PEPTIDE TRANSPORT• HANDLING PRECAUTIONS FOR PROTEIN &
PEPTIDE DRUGS• STERILISATION CONSIDERATIONS• REFERENCES
04/08/23 4
![Page 5: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/5.jpg)
INTRODUCTION : OPHTHALMIC PREPARATIONS ARE ADMINISTERED BY FOLLOWING WAYS • TOPICAL• INTRAOCULAR• PERIOCULAR
04/08/23 5
![Page 6: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/6.jpg)
• REQUIREMENTS :• STERILITY• TONICITY• TISSUE COMPATIBILITY• ABSENCE OF PYROGENS & PARTICULATE
MATTER
04/08/23 6
![Page 7: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/7.jpg)
• ANATOMY & PHYSIOLOGY OF EYE : CAN BE INSPECTED WITHOUT SURGICAL
INTERVENTION• EYELIDS : MECHANICAL PROTECTION OF GLOBE INNER SURFACES LUBRICATED BY TEARS
04/08/23 7
![Page 8: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/8.jpg)
04/08/23 8
![Page 9: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/9.jpg)
• STRUCTURE & FUNCTION OF EYEBALL:
HOUSED IN ORBIT COMPOSED OF THREE LAYERS : OUTER FIBROUS LAYER MIDDLE VASCULAR LAYER NEURAL RETINAL LAYER
04/08/23 9
![Page 10: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/10.jpg)
• LACRIMAL SYSTEM : CONJUNCTIVAL & CORNEAL SURFACES
LUBRICATED BY TEAR FILM
04/08/23 10
![Page 11: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/11.jpg)
LACRIMAL GLANDS SECRETE CLEAR WATERY SECRETION WHICH CONTAINS :
• NUMEROUS SALTS• GLUCOSE• 0.7% PROTEIN INCLUDING ENZYME
LYSOZYME
04/08/23 11
![Page 12: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/12.jpg)
THERAPEUTIC TARGETS :• TOPICAL• INTERNAL TISSUE
04/08/23 12
![Page 13: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/13.jpg)
Minimum Dosage Volume Concept :• Difficult To Design Dropper Configuration• Patient Cant Sense Small Volumes of 5 to 7.5
micro leters
04/08/23 13
![Page 14: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/14.jpg)
CORNEAL ABSORPTION : Effective than scleral absorption Hydrophillic drugs slowly absorbed than
lipophilic drugs. Corneal permeability is similar for all ions
suggesting that passage is through extracellular space
Molecular diameter: 10-25 Å
04/08/23 14
![Page 15: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/15.jpg)
PASSIVE DIFFUSION OCCURS ACROSS CORNEAL MEMBRANE
HYDROPHILIC DRUGS : PARACELLULAR TRANSPORT
LIPOPHILIC DRUGS : TRANSCELLULAR TRANSPORT
04/08/23 15
![Page 16: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/16.jpg)
• SCLERAL ABSORPTION : SCLERAL ABSORPTION IS PREFERRED
ROUTE FOR HYDROPHILIC DRUGS
04/08/23 16
![Page 17: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/17.jpg)
SYSTEMIC ABSORPTION : PRIMARILY THROUGH CONTACT WITH
NASAL & CONJUCTIVAL MUCOSAE LIPOIDAL CORNEAL EPITHELIUM FORMS
RELATIVELY IMPERMEABLE BARRIER WHICH PREVENTS PEPTIDES FROM EASILY ENTERING INTO SYSTEMIC CIRCULATION
04/08/23 17
![Page 18: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/18.jpg)
OPHTHALMIC DOSAGE FORMS
• OPHTHALMIC SOLUTIONS• GEL FORMING SOLUTIONS• POWDERS FOR SOLUTION• OPHTHALMIC GELS• OPHTHALMIC OINTMENTS• OPHTHALMIC EMULSIONS• OCULAR INSERTS• OPHTHALMIC SUSPENSIONS
04/08/23 18
![Page 19: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/19.jpg)
OPHTHALMIC SOLUTIONS :• DOSE UNIFORMITY• BRIEF CONTACT TIME• VISION INTERFERENCE MINIMALGEL FORMING SOLUTIONS : AQUEOUS BASED SOLUTION CONTAINING POLYMER
SYSTEMPOWDERS FOR SOLUTION : LIMITED STABILITY IN SOLUTION
04/08/23 19
![Page 20: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/20.jpg)
OPHTHALMIC GELS : GEL FORMING POLYMERS SUCH AS
CARBOMER USEDOPHTHALMIC OINTMENTS : ANHYDROUS BASE : MINERAL OIL WHITE PETROLATUM
04/08/23 20
![Page 21: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/21.jpg)
OPHTHALMIC EMULSIONS : O/W EMULSIONS – LESS IRRITATINGOCULAR INSERTS : NON ERODIBLE : OCUSERT PILO ERODIBLE : LACRISERTOCUSERT PILO : ZERO ORDER DRUG RELEASE NOT USED NOW. LACRISERT : HYDROXYPROPYL CELLULOSE FOR DRY EYE SYNDROME
04/08/23 21
![Page 22: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/22.jpg)
OPHTHALMIC SUSPENSIONS : LESS THAN 10 micrometer PARTICLE SIZE IS IDEAL. VEHICLE : SATURATED SOLUTION OF DRUG INCREASED DURATION OF ACTION SOLUBILITY : SMALL PARTICLES RETENTION : LARGE PARTICLES OPTIMUM PARTICLE SIZE DESIRED.
04/08/23 22
![Page 23: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/23.jpg)
PROBLEMS :• DOSE NON UNIFORMITY• PATIENT NON COMPLIANCE• POLYMORPHIC CHANGE
04/08/23 23
![Page 24: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/24.jpg)
CHARACTERISTICS OF OPHTHALMIC PREPARATIONS :
• CLARITY• BUFFER & pH• TONICITY
04/08/23 24
![Page 25: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/25.jpg)
INTRODUCTION TO PEPTIDES & PROTEINS
GREEK WORD PROTOS : FIRST
MORE THAN 50 AMINO ACIDS : PROTEINS
LESS THAN 50 AMINO ACIDS : PEPTIDES
04/08/23 25
![Page 26: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/26.jpg)
FUNCTIONS OF PROTEINS : • ENZYMATIC CATALYSIS• STORAGE TRANSPORT OF SMALL MOLECULES• MUSCLE CONTRACTION• MECHANICAL SUPPORT : COLLAGEN• IMMUNE PROTECTION : ANTIBODIES• GROWTH CONTROL VIA HORMONES
04/08/23 26
![Page 27: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/27.jpg)
STRUCTURE OF PROTEINS : MADE OF 20 AMINO ACIDSPRIMARY STRUCTURESECONDARY STRUCTURETERTIARY STRUCTUREQUATERNARY STRUCTURE
04/08/23 27
![Page 28: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/28.jpg)
BIOMEDICAL IMPORTANCE : PROTEINS : ESSENTIAL BODY FUNCTIONSHORMONE : INSULINANTIBIOTIC PEPTIDE : Gramicidin AANTITUMOUR AGENT : BLEOMYCIN
04/08/23 28
![Page 29: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/29.jpg)
NEED FOR PROTEIN PEPTIDE DRUG DELIVERY :
ADVANCES IN BIO-TECHNOLOGY COST EFFECTIVE AVAILABILITY PARENTERAL ADMINISTRATION
04/08/23 29
![Page 30: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/30.jpg)
FACTORS LIMITING USEFULNESS : INSTABILITIES POOR DISPOSITION PROFILES SUITABLE DELIVERY SYSTEMS ARE THUS
NECESSARY
04/08/23 30
![Page 31: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/31.jpg)
PEPTIDES & EYE :• PEPTIDES FOR LOCAL EFFECT : • BACITRACIN : ANTIBIOTIC• CYCLOSPORINE : TO PREVENT CORNEAL ALLOGRAFT
REJECTION• SYSTEMIC DELIVERY :• PROTEOLYTIC ENZYMES • CORNEAL BARRIER : IMPERMEABLE
04/08/23 31
![Page 32: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/32.jpg)
ADVANTAGES OF OCULAR DELIVERY :• CONVENIENT• RAPID SYSTEMIC ABSORPTION • BYPASS FIRST PASS METABOLISM• DOSE SIZE CONTROLLED ACCURATELYDISADVANTAGES : LOW SYSTEMIC BIOAVAILABILITY
04/08/23 32
![Page 33: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/33.jpg)
OTHER CONSIDERATIONS :• EYE DROPS SHOULD BE DEVOID OF LOCAL
IRRITATION• PERMEATION ENHANCERS MAY BE NEEDED• NOT MORE THAN 2.5 mg PEPTIDE CAN BE PLACED
IN EYE : NOT MORE THAN 25 microliters OF 10% w/v solution can be endured.
04/08/23 33
![Page 34: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/34.jpg)
MECHANISM OF PEPTIDE TRANSPORT : DEPENDS ON SIZE • PARACELLULAR ROUTE IS FAVOURED• CORNEA OFFERS GREATER RESISTANCE FOR
NEGATIVELY CHARGED COMPOUNDS[SMALL & MEDIUM SIZED PEPTIDES]
• INTERCELLULAR SPACES CAN BE WIDENED BY INFLAMMATION OF CORNEA
• SYSTEMIC ABSORPTION OCCURS THROUGH CONTACT WITH NASAL MUCOSA
04/08/23 34
![Page 35: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/35.jpg)
HANDLING PRECAUTIONS : • MAJOR PROBLEMS : AGGREGATION &
DENATURATION• PROTEIN TENDS TO UNDERGO SELF
ASSOCIATION TO FORM AGGREGATES• MATERIALS PREVENTING AGGREGATION: GLYCEROL LYSINE EDTA ASPARTIC ACID GLUTAMIC ACID
04/08/23 35
![Page 36: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/36.jpg)
DENATURATION : PROTEIN LOSES SECONDARY TERTIARY &/or
QUATERNARY STRUCTURETEMPERATURE : AT HIGH TEMPERATURE S-S BONDS BROKEN NEW S-S BONDS ARE FORMEDPRESSURE : NOT MUCH SENSITIVE TO PRESSURE
04/08/23 36
![Page 37: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/37.jpg)
LYOPHILIZATION : WATER REMOVED SALTS ELECTROLYTES CONCENTRATEDADDITIVES FOR PROTECTION :GLYCEROL GLUCOSESUCROSE
04/08/23 37
![Page 38: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/38.jpg)
STERILIZATION : AUTOCLAVING : TOO HARSHRADIATION : FREE RADICAL FORMATIONFILTRATION : ASEPTIC PROCESSING FOLLOWED
04/08/23 38
![Page 39: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/39.jpg)
REFERENCES :1) Lang JC, Roehrs RE. Ophthalmic Preparations.In : Troy DB, editor.
Remington : The Science and Practice of Pharmacy. 21st ed. Volume I Philadelphia : Lippincott Williams & Wilkins ; 2005.p.850-862
2) Agrawal S, Udupa N. Protein and peptide drug delivery : recent advances. In : Jain NK, editor. Progress in Controlled and novel drug delivery systems. 1st ed. Delhi : CBS Publishers; 2004.p.184-204
3) Erb RJ. Protein and Peptide therapeutics in the eye.In : Mitra AK editor. Ophthalmic Drug Delivery Systems. Volume 58. New York : Marcel Dekker Inc.p.437-440
4) Krishnamoorthy R. Ocular Delivery of Peptides and Proteins.In : Mitra AK,editor. Ophthalmic Drug Delivery Systems. Volume 58. New York : Marcel Dekker Inc.p.455-465
04/08/23 39
![Page 40: Ophthalmic Protein Peptide Drug Delivery](https://reader033.vdocuments.us/reader033/viewer/2022061119/546aa39ab4af9f5d6f8b486a/html5/thumbnails/40.jpg)
THANK YOU!
04/08/23 40